This company likely develops artificial intelligence solutions tailored for the healthcare sector. Their focus is on leveraging machine learning for applications such as diagnostics, patient management, or operational efficiency within medical systems. The core value proposition centers on integrating advanced AI technology to improve clinical outcomes and administrative processes in healthcare delivery.
Funding
$170K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Cancer research and treatment are hindered by fragmented and siloed health data, making it difficult to gain comprehensive insights into disease progression and treatment effectiveness, especially for diverse populations. The lack of integrated clinical, genomic, and patient-reported data limits the ability to personalize treatment plans and accelerate drug discovery.
Solution
OncoClarity offers a cancer monitoring platform that integrates longitudinal clinical data, genomic information, and patient-reported outcomes, providing a comprehensive view of the patient journey. By aggregating data from diverse sources, including EMRs, genomic sequencing, and patient surveys, the platform enables personalized health insights and informed clinical decision-making. The platform facilitates target identification, enhances clinical trial design, and provides real-world evidence to accelerate drug discovery and improve patient outcomes, particularly within Asian and emerging economies. OncoClarity's integrated datasets help researchers identify potential targets, design inclusive clinical trials, and optimize treatment protocols.
Target Audience
The primary target audience includes pharmaceutical companies, research institutions, and healthcare providers focused on oncology research, drug discovery, and personalized medicine, particularly those working with Asian patient populations.
Features
- Aggregates longitudinal clinical data sourced from EMRs, genomics and transcriptomics data, and patient-reported outcomes data (ePROM).
- Includes broad panel NGS data, whole genome sequence data, and RNA-seq data.
- Incorporates imaging data, including histopathology slides and radiological images (CT, PET-CT, Mammography, etc.).
- Provides access to over 1.5 million cancer patients' longitudinal records.
- Offers access to over 20,000 whole exome sequence raw data sets and 90,000 tissue samples across biobanks.
- Facilitates target identification and validation for specific research questions.
- Enhances patient recruitment and stratification for clinical trials.
- Enables comparative research for identifying unmet needs and protocol optimization studies.